Five years from now, the Food and Drug Administration expects it will be clearing 10 to 20 cell and gene therapy products a year. Yet while the arrival of gene therapy's moment may be clear, its effects on a healthcare system designed around chronic treatment are not.

INCLUDED IN THIS TRENDLINE

• Trends and challenges in the world of gene therapy today
• Roche hands $1B to Sarepta in major return to gene therapy deals
• Why gene editing companies oppose altering of embryos